Literature DB >> 23596673

CA 19-9 and pancreatic cancer.

Erxi Wu1, Shuang Zhou, Kruttika Bhat, Qingyong Ma.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23596673      PMCID： PMC3633106     

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


× No keyword cloud information.
  54 in total

Review 1.  Phases of biomarker development for early detection of cancer.

Authors:  M S Pepe; R Etzioni; Z Feng; J D Potter; M L Thompson; M Thornquist; M Winget; Y Yasui
Journal:  J Natl Cancer Inst       Date:  2001-07-18       Impact factor: 13.506

2.  Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients.

Authors:  H Narimatsu; H Iwasaki; F Nakayama; Y Ikehara; T Kudo; S Nishihara; K Sugano; H Okura; S Fujita; S Hirohashi
Journal:  Cancer Res       Date:  1998-02-01       Impact factor: 12.701

Review 3.  Advances in biomarker research for pancreatic cancer.

Authors:  Kruttika Bhat; Fengfei Wang; Qingyong Ma; Qinyu Li; Sanku Mallik; Tze-Chen Hsieh; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

4.  The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.

Authors:  Umashankar K Ballehaninna; Ronald S Chamberlain
Journal:  J Gastrointest Oncol       Date:  2012-06

5.  Unexpected occurrence of the Ca 19-9 tumor marker in normal human seminal plasma.

Authors:  G Uhlenbruck; U van Meensel-Maene; F G Hanisch; C Dienst
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1984-06

Review 6.  CA 19-9 in pancreatic cancer.

Authors:  R E Ritts; H A Pitt
Journal:  Surg Oncol Clin N Am       Date:  1998-01       Impact factor: 3.495

Review 7.  Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer.

Authors:  K S Goonetilleke; A K Siriwardena
Journal:  Eur J Surg Oncol       Date:  2006-11-09       Impact factor: 4.424

8.  The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer. A prospective study of 866 patients.

Authors:  T Frebourg; E Bercoff; N Manchon; J Senant; J P Basuyau; P Breton; A Janvresse; P Brunelle; J Bourreille
Journal:  Cancer       Date:  1988-12-01       Impact factor: 6.860

9.  The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays.

Authors:  Tingting Yue; Irwin J Goldstein; Michael A Hollingsworth; Karen Kaul; Randall E Brand; Brian B Haab
Journal:  Mol Cell Proteomics       Date:  2009-04-17       Impact factor: 5.911

Review 10.  Sialyl Lewis(a): a tumor-associated carbohydrate antigen involved in adhesion and metastatic potential of cancer cells.

Authors:  Maciej Ugorski; Anna Laskowska
Journal:  Acta Biochim Pol       Date:  2002       Impact factor: 2.149
View more
  12 in total

1.  Lateral flow assay for carbohydrate antigen 19-9 in whole blood by using magnetized carbon nanotubes.

Authors:  Yan Huang; Yongqiang Wen; Kwaku Baryeh; Sunitha Takalkar; Michelle Lund; Xueji Zhang; Guodong Liu
Journal:  Mikrochim Acta       Date:  2017-08-25       Impact factor: 5.833

2.  Interrogation of multidrug resistance (MDR1) P-glycoprotein (ABCB1) expression in human pancreatic carcinoma cells: correlation of 99mTc-Sestamibi uptake with western blot analysis.

Authors:  Scott E Harpstrite; Hannah Gu; Radhika Natarajan; Vijay Sharma
Journal:  Nucl Med Commun       Date:  2014-10       Impact factor: 1.690

3.  Combined detection of serum UL16-binding protein 2 and macrophage inhibitory cytokine-1 improves early diagnosis and prognostic prediction of pancreatic cancer.

Authors:  Yu-Fen Zhou; Ling-Xiao Xu; Li-Ya Huang; Fang Guo; Fan Zhang; Xiang-Yi He; Yao-Zong Yuan; Wei-Yan Yao
Journal:  Oncol Lett       Date:  2014-08-08       Impact factor: 2.967

Review 4.  Molecular Imaging of Pancreatic Cancer with Antibodies.

Authors:  Christopher G England; Reinier Hernandez; Savo Bou Zein Eddine; Weibo Cai
Journal:  Mol Pharm       Date:  2015-12-10       Impact factor: 4.939

5.  lncRNA MALAT1, HOTTIP and PVT1 as predictors for predicting the efficacy of GEM based chemotherapy in first-line treatment of pancreatic cancer patients.

Authors:  Cui-Juan Wang; Sheng-Bin Shi; Jing Tian; Jun Xu; Zuo-Xing Niu
Journal:  Oncotarget       Date:  2017-07-18

6.  Use of autoantibodies against tumor-associated antigens as serum biomarkers for primary screening of cervical cancer.

Authors:  Yingji Jin; Seung Cheol Kim; Hyoung Jin Kim; Woong Ju; Yun Hwan Kim; Hong-Jin Kim
Journal:  Oncotarget       Date:  2017-11-01

7.  CD63-GPC1-Positive Exosomes Coupled with CA19-9 Offer Good Diagnostic Potential for Resectable Pancreatic Ductal Adenocarcinoma.

Authors:  Etienne Buscail; Alexandre Chauvet; Pascaline Quincy; Olivier Degrandi; Camille Buscail; Isabelle Lamrissi; Isabelle Moranvillier; Charline Caumont; Severine Verdon; Alain Brisson; Marion Marty; Laurence Chiche; Christophe Laurent; Veronique Vendrely; François Moreau-Gaudry; Aurelie Bedel; Sandrine Dabernat
Journal:  Transl Oncol       Date:  2019-08-07       Impact factor: 4.243

8.  Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls.

Authors:  Nicholas Willumsen; Cecilie L Bager; Diana J Leeming; Victoria Smith; Morten A Karsdal; David Dornan; Anne-Christine Bay-Jensen
Journal:  BMC Cancer       Date:  2013-11-21       Impact factor: 4.430

9.  Salivary HOTAIR and PVT1 as novel biomarkers for early pancreatic cancer.

Authors:  Zijun Xie; Xiaoliang Chen; Jianzhong Li; Yunwei Guo; Haijiao Li; Xuemei Pan; Jie Jiang; Huiling Liu; Bin Wu
Journal:  Oncotarget       Date:  2016-05-03

Review 10.  The Diagnostic Dilemma of Malignant Biliary Strictures.

Authors:  Robert Dorrell; Swati Pawa; Yi Zhou; Neeraj Lalwani; Rishi Pawa
Journal:  Diagnostics (Basel)       Date:  2020-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.